Trial Search Results

Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic

The purpose of this study is to investigate whether an empirically validated treatment for insomnia (CBT-I) administered early in the course of sleep disturbance can prevent insomnia disorder or lessen negative mental health outcomes in the wake of the COVID-19 crisis in adults.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Behavioral: Remote Cognitive Behavioral Therapy for Insomnia




Inclusion Criteria:

   - Age 18 years or older

   - Access to the internet

   - Subjective complaint of sleep disturbance (ISI ≥10) that began after March 1, 2020 or
   the COVID-19 Pandemic (self-reported during DUKE Interview)

   - Lives in the United States

Exclusion Criteria:

   - Presence of suicidal ideation representing high risk as measured by the
   Sheehan-Suicide Tracking Scale (S-STS).

   - Use of medication specifically prescribed for sleep disturbance and unwilling or
   unable to discontinue more than one week prior to baseline data collection.

   - Current or lifetime history of bipolar disorder or psychosis

   - Current substance abuse or dependence

   - Not able to verbalize understanding of involvement in research and provide written,
   informed consent

   - Not fluent or literate in English

   - Unstable pharmacotherapy for other mental health disorders

   - Severe impediment to vision, hearing, and/or hand movement, likely to interfere with
   the ability to complete assessments, or are unable and/or unlikely to follow study

   - Working rotating shift that overlaps with 2400h

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Andrea Goldstein-Piekarski, PhD